Physician profile
Preetham Reddy
NPI 1053576058
$8,899.65
in general payments reported to CMS, 2019-2025
29 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,249 · 2020: $2,193 · 2021: $59.63 · 2022: $790 · 2023: $1,044 · 2024: $434 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3,727.09 | 2019-2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $2,186.81 | 2020-2023 | Definity |
| Medtronic, INC. | $424.27 | 2022 | |
| Horizon Therapeutics Plc | $363.51 | 2022-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $259.15 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $255.86 | 2019-2024 | |
| Amgen INC. | $252.08 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $196.76 | 2022-2025 | |
| Philips North America LLC | $159.04 | 2020-2024 | (Ck4) Mcot, (Ck7) Extended Holter |
| Janssen Pharmaceuticals, INC | $151.54 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $150.91 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $148.28 | 2019-2024 | |
| Boston Scientific Corporation | $102.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.18 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $61.71 | 2022-2023 | Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $45.25 | 2021-2022 | |
| Astellas Pharma US INC | $44.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $42.31 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $34.79 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $31.91 | 2023-2024 | Amvuttra |
| Heartflow, INC. | $30.37 | 2024 | |
| Siemens Medical Solutions USA, INC. | $27.33 | 2023 | Biograph Horizon-3r |
| Actelion Pharmaceuticals US, INC. | $22.76 | 2022 | |
| Bardy Diagnostics, INC. | $19.00 | 2022 | |
| Daiichi Sankyo INC. | $17.49 | 2023 | Injectafer |
| Akcea Therapeutics, INC. | $15.90 | 2019 | |
| Amarin Pharma, INC. | $14.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.56 | 2019 | |
| Esperion Therapeutics, INC. | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preetham Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.